We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TEGENERO FILES FOR BANKRUPTCY AFTER CATASTROPHIC CLINICAL TRIAL

TEGENERO FILES FOR BANKRUPTCY AFTER CATASTROPHIC CLINICAL TRIAL

July 6, 2006

TeGenero, the German pharmaceutical startup whose UK-based clinical trial for its immune-boosting drug TGN1412 caused severe adverse reactions in six healthy male volunteers, has announced that it filed for bankruptcy protection in a court in Wurzburg, Germany, on July 4.

"The unforeseeable adverse reactions caused by TGN1412 in the TGN1412-HV Phase I trial have made it impossible to attract the investment necessary for the company to continue operations," the firm said in a statement.

The six affected participants fell ill on March 13, within hours of taking the investigational drug at the trial site at Northwick Park hospital in London. According to media reports, one of the trial participants, a trainee plumber named Ryan Wilson, is still confined to a wheelchair after suffering heart, liver and kidney failure, as well as pneumonia and septicemia.

TeGenero said that investigations conducted by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Germany's Paul-Ehrlich-Institut "have identified no deficiencies" in the preclinical testing of the drug, and that the adverse events "were completely unforeseeable."

According to an April 6 statement from the German agency, "Low dosages of the trial medicine did not cause any adverse effects in the primates tested. Higher dosages caused only mild transient reactions. A very low dose, 1/160 of that used without adverse effects on monkeys, was used on humans." The MHRA said that the trial "was run according to the agreed protocol, and the correct dose of the product was given to the patients."

However, other reports indicated that the drug caused swollen glands in some of the test monkeys. One volunteer who received a placebo said the informed consent document was hard to read and he was pressured to sign it within 10 to 15 minutes.

The trial was conducted by the contract research organization Parexel, which cited the MHRA report on the trial in disclaiming responsibility. "Although there were certain discrepancies identified in the MHRA report, there were no issues that contributed to the adverse reactions experienced by the volunteers, despite the fact that this was a highly challenging situation," Herman Scholtz, head of Parexel International Clinical Pharmacology, said in a May 25 statement.

TeGenero said the trial participants' claims for compensation will continue to be handled by the firm's insurers. "TeGenero has been supporting the official investigations as well as developing laboratory tests of its own to try to establish what happened in the trial," the company said. "TeGenero will continue to make its expertise available for the purposes of such investigations to the fullest possible extent." (http://www.fdanews.com/did/5_131/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing